肝细胞癌降期结局:MERITS-LT多中心研究
MERITS-LT多中心前瞻性研究纳入209例符合UNOS-DS标准的肝细胞癌患者,2年降期成功概率为87.7%、脱落率37.3%,初始治疗为TACE或Y90无差异,3年肝移植概率46.6%,移植后2年生存率95%,但42.8%超出米兰标准(低估分期)。
要点
- UNOS-DS标准下降期成功率>80%,TACE与Y90疗效相似。
- 凝集素反应性AFP≥10%与脱落风险增加相关(HR 3.7)。
- 移植后2年生存率95%,但42.8%存在肿瘤低估分期。
核心结论
- 在基于UNOS-DS标准的前瞻性多区域研究中,降期成功率>80%,TACE与Y90作为初始降期治疗疗效相似。
- 尽管移植后2年生存率95%,肿瘤低估分期率仍较高。
研究设计与样本
- 首个多区域前瞻性研究,纳入7个中心、4个UNOS区域,2016-2019年连续209例接受基于UNOS-DS标准降期的HCC患者。
主要发现
- 2年降期成功至米兰标准的概率为87.7%,自初始降期操作起2年脱落率为37.3%。
- TACE(n=132)与Y90(n=62)作为初始降期治疗在mRECIST应答、降期成功概率或时间、等待名单脱落或肝移植方面无差异。
- 3年肝移植概率为46.6%,中位等待时间17.2个月;移植后2年生存率95%,HCC复发率7.9%。
- 移植标本中17.5%有血管侵犯,42.8%超出米兰标准(低估分期);唯一与低估分期相关的因素是末次移植前影像的病灶数目加最大肿瘤直径之和,每增加1单位低估分期风险增加35%。
临床怎么用
- UNOS-DS标准可用于肝细胞癌降期患者选择,TACE或Y90均可作为初始降期治疗。
- 凝集素反应性AFP≥10%提示脱落风险较高,需加强监测。
- 移植前影像病灶数目与最大直径之和可辅助评估低估分期风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: United Network of Organ Sharing (UNOS) has adopted uniform criteria for downstaging (UNOS-DS) of hepatocellular carcinoma (HCC) before liver transplantation (LT), but the downstaging success rate and intention-to-treat outcomes across broad geographic regions are unknown. METHODS: In this first multiregional study (7 centers, 4 UNOS regions), 209 consecutive patients with HCC undergoing downstaging based on UNOS-DS criteria were prospectively evaluated from 2016 to 2019. RESULTS: Probability of successful downstaging to Milan criteria and dropout at 2 years from the initial downstaging procedure was 87.7% and 37.3%, respectively. Pretreatment with lectin-reactive α-fetoprotein ≥10% (hazard ratio, 3.7; P = .02) was associated with increased dropout risk. When chemoembolization (n = 132) and yttrium-90 radioembolization (n = 62) were compared as the initial downstaging treatment, there were no differences in Modified Response Evaluation Criteria In Solid Tumors response, probability of or time to successful downstaging, waiting list dropout, or LT. Probability of LT at 3 years was 46.6% after a median of 17.2 months. In the explant, 17.5% had vascular invasion, and 42.8% exceeded Milan criteria (understaging). The only factor associated with understaging was the sum of the number of lesions plus largest tumor diameter on the last pre-LT imaging, and the odds of understaging increased by 35% per 1-unit increase in this sum. Post-LT survival at 2 years was 95%, and HCC recurrence occurred in 7.9%. CONCLUSION: In this first prospective multiregional study based on UNOS-DS criteria, we observed a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. A high rate of tumor understaging was observed despite excellent 2-year post-LT survival of 95%. Additional LRT to reduce viable tumor burden may reduce tumor understaging.
引用
- Mehta N, Frenette C, Tabrizian P, et al. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021. PMID: 34331914. doi:10.1053/j.gastro.2021.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。